RE:RE:RE:RE:RE:RE:RE:RE:RE:No follow throughThere will be a NR released if there is anything material being presented. It's not that difficult releasing news and then presenting. Not sure why you'd want a halt. They are only good for blockbuster news, SVA news is going to be up for interpretation. Some people may think its good and others will think it could have been much better. The number of each will determine which way the price goes. If I was a gambling man, I'd say the price will go up and then settle down by days end. It's a risky move what they've done. There is nothing else for anyone to look forward to, so if the news is meh, the price will suffer. Phil is a one play at a time kinda guy which doesn't bode well for a CEO of a small cap biotech company. He needs to get back to his "multiple shots on goal" analogy he used to reference all the time. We need Hemo, we need Thyroid, and any other indication in the clinic. Not just a couple of images on a presentation with a progress bar that hasn't budged for years. There is no reason why sigalion should be ahead of us with Hemo in the clinic. We have proved the tech in mice years ago and not a peep since. Wake up Phil, strike while the iron is hot or risk losing it all.